Valuation: Genmab A/S

Market Cap 128B 20.06B 17.18B 16.08B 14.72B 27.62B 1,919B 27.98B 190B 74.07B 964B 75.32B 73.68B 3,189B P/E 2026 *
27.2x
P/E 2027 * 19.2x
Enterprise Value 148B 23.12B 19.81B 18.53B 16.97B 31.84B 2,212B 32.26B 219B 85.39B 1,111B 86.83B 84.94B 3,676B EV / Sales 2026 *
5.1x
EV / Sales 2027 * 4.14x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+6.12%
Current month+15.74%
1 month+12.56%
3 months+24.80%
6 months+16.05%
Current year+6.12%
1 week 2,047
Extreme 2047
2,187
1 month 1,819.5
Extreme 1819.5
2,187
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+6.12%+37.01%-15.31% 20.06B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
-0.41%+0.54%+308.39%+206.94% 12.3B
Average +1.09%+7.59%+84.02%+198.60% 30.18B
Weighted average by Cap. +0.69%+9.12%+68.23%+159.86%

Financials

2026 *2027 *
Net sales 29.01B 4.53B 3.88B 3.63B 3.32B 6.24B 434B 6.32B 42.91B 16.73B 218B 17.01B 16.64B 720B 33.71B 5.26B 4.51B 4.22B 3.86B 7.25B 504B 7.35B 49.86B 19.44B 253B 19.77B 19.34B 837B
Net income 4.93B 770M 659M 617M 565M 1.06B 73.65B 1.07B 7.29B 2.84B 37B 2.89B 2.83B 122B 7.13B 1.11B 954M 893M 817M 1.53B 107B 1.55B 10.55B 4.11B 53.52B 4.18B 4.09B 177B
Net Debt 19.62B 3.06B 2.63B 2.46B 2.25B 4.22B 293B 4.28B 29.02B 11.32B 147B 11.51B 11.26B 487B 11.13B 1.74B 1.49B 1.39B 1.28B 2.39B 166B 2.43B 16.46B 6.42B 83.56B 6.53B 6.39B 276B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-21 DKK 2,151.00 +0.47% 122,551
26-08-20 DKK 2,141.00 -0.51% 144,089
26-08-19 DKK 2,152.00 +2.28% 99,873
26-08-18 DKK 2,104.00 0.00% 108,957
26-08-17 DKK 2,104.00 +3.80% 177,078
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,151.00DKK
Average target price
2,410.46DKK
Spread / Average Target
+12.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock